Canada Markets open in 23 mins

FSD Pharma Congratulates High Tide on the Resumption of Retail Cannabis Licensing by AGLC in Alberta

TORONTO, May 31, 2019 /CNW/ - FSD Pharma Inc. (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) ("FSD" or the "Company") would like to congratulate High Tide Inc. (CSE:HITI) (OTCQB:HITIF - News) (FRA:2LY.F - News) ("High Tide") on the recent announcement from Alberta Gaming, Liquor and Cannabis lifting the moratorium on issuing cannabis licenses and accepting license applications. The announcement is an encouraging sign of steadily improving cannabis supply levels in Alberta and is a positive step for companies like High Tide that have numerous stores ready and waiting to retail cannabis products.

FSD Pharma Inc. (CNW Group/FSD Pharma Inc.)

As a strategic investor in High Tide, FSD Pharma is pleased to see changes that will support the continued growth and success of the cannabis industry as well as the companies in which it is invested. FSD Pharma will remain a supporter of High Tide and will continue to work collaboratively with it as a cannabis retailer enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products.

"In addition to High Tide's existing retail locations in Alberta, Saskatchewan, and Ontario, this lifting of the moratorium will allow the company to increase its return on the investments it has made on infrastructure. This will offer a number of new and exciting retail locations for Albertans and we see further value in our partner High Tide," said Dr. Raza Bokhari, FSD Executive Co-Chairman & Chief Executive Officer.

For more information on FSD Pharma: https://fsdpharma.com

About FSD Pharma

FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company has 25,000 square feet that is licensed at its Ontario facility and expansion is currently underway.

FSD facilities sit on 70 acres of land with 40 acres primed for development with an expansion plan of up to 3,896,000 square feet by 2025.

FSD's wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its Sale for Medical Purposes license on April 18, 2019. FV Pharma's vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

Forward-Looking Information

Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on FSD Pharma's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Actual results and developments may differ materially from those contemplated by these. The forward-looking information contained in this press release is made as of the date hereof, and FSD Pharma is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

SOURCE FSD Pharma Inc.


View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/31/c6161.html